Novo Nordisk A/S, a leading global healthcare company, has successfully completed the reduction of its B share capital as announced at its Annual General Meeting on March 21, 2024. The reduction involved the cancellation of 45,000,000 B shares, resulting in a decrease of the B share capital from DKK 343,512,800 to DKK 339,012,800. Following the reduction, the total share capital of Novo Nordisk stands at DKK 446,500,000, split into A and B shares. The company confirmed that this capital adjustment will not impact its ongoing share repurchase program. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.

Novo Nordisk A/S, a leading global healthcare company, has successfully completed the reduction of its B share capital as announced at its Annual General Meeting on March 21, 2024. The reduction involved the cancellation of 45,000,000 B shares, resulting in a decrease of the B share capital from DKK 343,512,800 to DKK 339,012,800. Following the reduction, the total share capital of Novo Nordisk stands at DKK 446,500,000, split into A and B shares. The company confirmed that this capital adjustment will not impact its ongoing share repurchase program. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.